메뉴 건너뛰기




Volumn 18, Issue 4, 2011, Pages 300-311

Off the Beaten Renin-Angiotensin-Aldosterone System Pathway: New Perspectives on Antiproteinuric Therapy

Author keywords

Albuminuria; Diabetes; Glomerulus; Novel therapies; Podocyte; Proteinuria

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADALIMUMAB; ANTITHROMBOCYTIC AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CORTICOTROPIN; CYCLOSPORIN; DEXAMETHASONE; ENDOTHELIN RECEPTOR ANTAGONIST; ETANERCEPT; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; MYCOPHENOLIC ACID; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR; RETINOID; RITUXIMAB; RUBOXISTAURIN; SULODEXIDE; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; TRIPTOLIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; VASCULOTROPIN; VITAMIN D DERIVATIVE;

EID: 79960539964     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2011.06.002     Document Type: Review
Times cited : (12)

References (127)
  • 1
    • 70349243437 scopus 로고    scopus 로고
    • Emerging therapies for chronic kidney disease: what is their role?
    • Vilayur E., Harris D.C. Emerging therapies for chronic kidney disease: what is their role?. Nat Rev Nephrol 2009, 5:375-383.
    • (2009) Nat Rev Nephrol , vol.5 , pp. 375-383
    • Vilayur, E.1    Harris, D.C.2
  • 2
    • 77949541746 scopus 로고    scopus 로고
    • Proteinuria: an enzymatic disease of the podocyte?
    • Mundel P., Reiser J. Proteinuria: an enzymatic disease of the podocyte?. Kidney Int 2010, 77:571-580.
    • (2010) Kidney Int , vol.77 , pp. 571-580
    • Mundel, P.1    Reiser, J.2
  • 3
    • 70249101386 scopus 로고    scopus 로고
    • Therapeutic targets in the podocyte: findings in anti-slit diaphragm antibody-induced nephropathy
    • Kawachi H., Han G.D., Miyauchi N., Hashimoto T., Suzuki K., Shimizu F. Therapeutic targets in the podocyte: findings in anti-slit diaphragm antibody-induced nephropathy. J Nephrol 2009, 22:450-456.
    • (2009) J Nephrol , vol.22 , pp. 450-456
    • Kawachi, H.1    Han, G.D.2    Miyauchi, N.3    Hashimoto, T.4    Suzuki, K.5    Shimizu, F.6
  • 5
    • 77950517549 scopus 로고    scopus 로고
    • Toward the development of podocyte-specific drugs
    • Reiser J., Gupta V., Kistler A.D. Toward the development of podocyte-specific drugs. Kidney Int 2010, 77:662-668.
    • (2010) Kidney Int , vol.77 , pp. 662-668
    • Reiser, J.1    Gupta, V.2    Kistler, A.D.3
  • 8
    • 67649134882 scopus 로고    scopus 로고
    • Reduction in VEGF protein and phosphorylated nephrin associated with proteinuria in adriamycin nephropathy rats
    • Fan Q., Xing Y., Ding J., Guan N. Reduction in VEGF protein and phosphorylated nephrin associated with proteinuria in adriamycin nephropathy rats. Nephron Exp Nephrol 2009, 111:e92-e102.
    • (2009) Nephron Exp Nephrol , vol.111
    • Fan, Q.1    Xing, Y.2    Ding, J.3    Guan, N.4
  • 9
    • 33646133214 scopus 로고    scopus 로고
    • The effect of dexamethasone on defective nephrin transport caused by ER stress: a potential mechanism for the therapeutic action of glucocorticoids in the acquired glomerular diseases
    • Fujii Y., Khoshnoodi J., Takenaka H., et al. The effect of dexamethasone on defective nephrin transport caused by ER stress: a potential mechanism for the therapeutic action of glucocorticoids in the acquired glomerular diseases. Kidney Int 2006, 69:1350-1359.
    • (2006) Kidney Int , vol.69 , pp. 1350-1359
    • Fujii, Y.1    Khoshnoodi, J.2    Takenaka, H.3
  • 10
    • 16244409244 scopus 로고    scopus 로고
    • Differential proteomic analysis of proteins induced by glucocorticoids in cultured murine podocytes
    • Ransom R.F., Vega-Warner V., Smoyer W.E., Klein J. Differential proteomic analysis of proteins induced by glucocorticoids in cultured murine podocytes. Kidney Int 2005, 67:1275-1285.
    • (2005) Kidney Int , vol.67 , pp. 1275-1285
    • Ransom, R.F.1    Vega-Warner, V.2    Smoyer, W.E.3    Klein, J.4
  • 11
    • 2442505604 scopus 로고    scopus 로고
    • ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses
    • Berg A.L., Arnadottir M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol Dial Transplant 2004, 19:1305-1307.
    • (2004) Nephrol Dial Transplant , vol.19 , pp. 1305-1307
    • Berg, A.L.1    Arnadottir, M.2
  • 12
    • 31044441980 scopus 로고    scopus 로고
    • A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy
    • Ponticelli C., Passerini P., Salvadori M., et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 2006, 47:233-240.
    • (2006) Am J Kidney Dis , vol.47 , pp. 233-240
    • Ponticelli, C.1    Passerini, P.2    Salvadori, M.3
  • 13
    • 77955609123 scopus 로고    scopus 로고
    • Melanocortin 1 receptor agonists reduce proteinuria
    • Lindskog A., Ebefors K., Johansson M.E., et al. Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol 2010, 21:1290-1298.
    • (2010) J Am Soc Nephrol , vol.21 , pp. 1290-1298
    • Lindskog, A.1    Ebefors, K.2    Johansson, M.E.3
  • 14
    • 51349162919 scopus 로고    scopus 로고
    • The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A
    • Faul C., Donnelly M., Merscher-Gomez S., et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008, 14:931-938.
    • (2008) Nat Med , vol.14 , pp. 931-938
    • Faul, C.1    Donnelly, M.2    Merscher-Gomez, S.3
  • 15
    • 77954534869 scopus 로고    scopus 로고
    • Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies
    • Bensman A., Niaudet P. Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies. Pediatr Nephrol 2010, 25:1197-1199.
    • (2010) Pediatr Nephrol , vol.25 , pp. 1197-1199
    • Bensman, A.1    Niaudet, P.2
  • 16
    • 34250175849 scopus 로고    scopus 로고
    • Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats
    • Zhang Y., Chen B., Hou X.H., et al. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats. Chin Med J (Engl) 2007, 120:988-995.
    • (2007) Chin Med J (Engl) , vol.120 , pp. 988-995
    • Zhang, Y.1    Chen, B.2    Hou, X.H.3
  • 17
  • 18
    • 77951490147 scopus 로고    scopus 로고
    • The accumulated experience with the use of mycophenolate mofetil in primary glomerulonephritis
    • Koukoulaki M., Goumenos D.S. The accumulated experience with the use of mycophenolate mofetil in primary glomerulonephritis. Expert Opin Investig Drugs 2010, 19:673-687.
    • (2010) Expert Opin Investig Drugs , vol.19 , pp. 673-687
    • Koukoulaki, M.1    Goumenos, D.S.2
  • 19
    • 68549117277 scopus 로고    scopus 로고
    • Monoclonal antibodies for podocytopathies: rationale and clinical responses
    • Marasa M., Kopp J.B. Monoclonal antibodies for podocytopathies: rationale and clinical responses. Nat Rev Nephrol 2009, 5:337-348.
    • (2009) Nat Rev Nephrol , vol.5 , pp. 337-348
    • Marasa, M.1    Kopp, J.B.2
  • 20
    • 77950362581 scopus 로고    scopus 로고
    • Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine
    • Fujinaga S., Hirano D., Nishizaki N., et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol 2010, 25:539-544.
    • (2010) Pediatr Nephrol , vol.25 , pp. 539-544
    • Fujinaga, S.1    Hirano, D.2    Nishizaki, N.3
  • 21
    • 79960553247 scopus 로고    scopus 로고
    • Effect of rituximab on the regulation of sphingomyelinase-like phosphodiesterase 3b-precursor in recurrent FSGS. Poster presented at: American Society of Nephrology Annual Meeting; Denver, CO
    • Fornoni A, Sagheshima J. Effect of rituximab on the regulation of sphingomyelinase-like phosphodiesterase 3b-precursor in recurrent FSGS. Poster presented at: American Society of Nephrology Annual Meeting; 2010; Denver, CO.
    • (2010)
    • Fornoni, A.1    Sagheshima, J.2
  • 23
    • 0033917537 scopus 로고    scopus 로고
    • Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo
    • Grande J.P., Walker H.J., Holub B.J., et al. Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo. Kidney Int 2000, 57:1027-1040.
    • (2000) Kidney Int , vol.57 , pp. 1027-1040
    • Grande, J.P.1    Walker, H.J.2    Holub, B.J.3
  • 24
    • 66849102001 scopus 로고    scopus 로고
    • The effect of n-3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials
    • Miller E.R., Juraschek S.P., Appel L.J., et al. The effect of n-3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials. Am J Clin Nutr 2009, 89:1937-1945.
    • (2009) Am J Clin Nutr , vol.89 , pp. 1937-1945
    • Miller, E.R.1    Juraschek, S.P.2    Appel, L.J.3
  • 25
    • 77952689528 scopus 로고    scopus 로고
    • Suppression of nephrin expression by TNF-alpha via interfering with the cAMP-retinoic acid receptor pathway
    • Saito Y., Okamura M., Nakajima S., et al. Suppression of nephrin expression by TNF-alpha via interfering with the cAMP-retinoic acid receptor pathway. Am J Physiol Renal Physiol 2010, 298:F1436-F1444.
    • (2010) Am J Physiol Renal Physiol , vol.298
    • Saito, Y.1    Okamura, M.2    Nakajima, S.3
  • 26
    • 0032782860 scopus 로고    scopus 로고
    • TNF-alpha induces actin cytoskeleton reorganization in glomerular epithelial cells involving tyrosine phosphorylation of paxillin and focal adhesion kinase
    • Koukouritaki S.B., Vardaki E.A., Papakonstanti E.A., Lianos E., Stournaras C., Emmanouel D.S. TNF-alpha induces actin cytoskeleton reorganization in glomerular epithelial cells involving tyrosine phosphorylation of paxillin and focal adhesion kinase. Mol Med 1999, 5:382-392.
    • (1999) Mol Med , vol.5 , pp. 382-392
    • Koukouritaki, S.B.1    Vardaki, E.A.2    Papakonstanti, E.A.3    Lianos, E.4    Stournaras, C.5    Emmanouel, D.S.6
  • 27
    • 67651085542 scopus 로고    scopus 로고
    • Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study
    • Lionaki S., Siamopoulos K., Theodorou I., et al. Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study. Nephrol Dial Transplant 2009, 24:2144-2150.
    • (2009) Nephrol Dial Transplant , vol.24 , pp. 2144-2150
    • Lionaki, S.1    Siamopoulos, K.2    Theodorou, I.3
  • 28
    • 71849107687 scopus 로고    scopus 로고
    • Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group
    • Joy M.S., Gipson D.S., Powell L., et al. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis 2010, 55:50-60.
    • (2010) Am J Kidney Dis , vol.55 , pp. 50-60
    • Joy, M.S.1    Gipson, D.S.2    Powell, L.3
  • 30
    • 77950208651 scopus 로고    scopus 로고
    • Effects of TGF-beta on podocyte growth and disease progression in proliferative podocytopathies
    • Lee H.S., Song C.Y. Effects of TGF-beta on podocyte growth and disease progression in proliferative podocytopathies. Kidney Blood Press Res 2010, 33:24-29.
    • (2010) Kidney Blood Press Res , vol.33 , pp. 24-29
    • Lee, H.S.1    Song, C.Y.2
  • 31
    • 31644431555 scopus 로고    scopus 로고
    • The cyclin-dependent kinase inhibitor p21 is required for TGF-beta1-induced podocyte apoptosis
    • Wada T., Pippin J.W., Terada Y., Shankland S.J. The cyclin-dependent kinase inhibitor p21 is required for TGF-beta1-induced podocyte apoptosis. Kidney Int 2005, 68:1618-1629.
    • (2005) Kidney Int , vol.68 , pp. 1618-1629
    • Wada, T.1    Pippin, J.W.2    Terada, Y.3    Shankland, S.J.4
  • 32
    • 0034836835 scopus 로고    scopus 로고
    • Apoptosis in podocytes induced by TGF-beta and Smad7
    • Schiffer M., Bitzer M., Roberts I.S., et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001, 108:807-816.
    • (2001) J Clin Invest , vol.108 , pp. 807-816
    • Schiffer, M.1    Bitzer, M.2    Roberts, I.S.3
  • 33
    • 0038205926 scopus 로고    scopus 로고
    • Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat
    • Benigni A., Zoja C., Corna D., et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003, 14:1816-1824.
    • (2003) J Am Soc Nephrol , vol.14 , pp. 1816-1824
    • Benigni, A.1    Zoja, C.2    Corna, D.3
  • 34
    • 36048950801 scopus 로고    scopus 로고
    • Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria
    • Wang A., Ziyadeh F.N., Lee E.Y., et al. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am J Physiol Renal Physiol 2007, 293:F1657-F1665.
    • (2007) Am J Physiol Renal Physiol , vol.293
    • Wang, A.1    Ziyadeh, F.N.2    Lee, E.Y.3
  • 35
    • 24944563923 scopus 로고    scopus 로고
    • ATRA induces podocyte differentiation and alters nephrin and podocin expression in vitro and in vivo
    • Vaughan M.R., Pippin J.W., Griffin S.V., et al. ATRA induces podocyte differentiation and alters nephrin and podocin expression in vitro and in vivo. Kidney Int 2005, 68:133-144.
    • (2005) Kidney Int , vol.68 , pp. 133-144
    • Vaughan, M.R.1    Pippin, J.W.2    Griffin, S.V.3
  • 36
    • 73449096477 scopus 로고    scopus 로고
    • PTH-induced internalization of apical membrane NaPi2a: role of actin and myosin VI
    • Blaine J., Okamura K., Giral H., et al. PTH-induced internalization of apical membrane NaPi2a: role of actin and myosin VI. Am J Physiol Cell Physiol 2009, 297:C1339-C1346.
    • (2009) Am J Physiol Cell Physiol , vol.297
    • Blaine, J.1    Okamura, K.2    Giral, H.3
  • 37
    • 33845973761 scopus 로고    scopus 로고
    • Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway
    • He J.C., Lu T.C., Fleet M., et al. Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway. J Am Soc Nephrol 2007, 18:93-102.
    • (2007) J Am Soc Nephrol , vol.18 , pp. 93-102
    • He, J.C.1    Lu, T.C.2    Fleet, M.3
  • 38
    • 0037378798 scopus 로고    scopus 로고
    • Retinoids regulate the repairing process of the podocytes in puromycin aminonucleoside-induced nephrotic rats
    • Suzuki A., Ito T., Imai E., et al. Retinoids regulate the repairing process of the podocytes in puromycin aminonucleoside-induced nephrotic rats. J Am Soc Nephrol 2003, 14:981-991.
    • (2003) J Am Soc Nephrol , vol.14 , pp. 981-991
    • Suzuki, A.1    Ito, T.2    Imai, E.3
  • 39
    • 9444258635 scopus 로고    scopus 로고
    • Effect of retinoic acid in experimental diabetic nephropathy
    • Han S.Y., So G.A., Jee Y.H., et al. Effect of retinoic acid in experimental diabetic nephropathy. Immunol Cell Biol 2004, 82:568-576.
    • (2004) Immunol Cell Biol , vol.82 , pp. 568-576
    • Han, S.Y.1    So, G.A.2    Jee, Y.H.3
  • 40
    • 33846686500 scopus 로고    scopus 로고
    • Therapeutic effect of all-trans-retinoic acid (at-RA) on an autoimmune nephritis experimental model: role of the VLA-4 integrin
    • Escribese M.M., Conde E., Martin A., et al. Therapeutic effect of all-trans-retinoic acid (at-RA) on an autoimmune nephritis experimental model: role of the VLA-4 integrin. BMC Nephrol 2007, 8:3.
    • (2007) BMC Nephrol , vol.8 , pp. 3
    • Escribese, M.M.1    Conde, E.2    Martin, A.3
  • 41
    • 49749144405 scopus 로고    scopus 로고
    • Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease
    • Fried L.F. Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. Kidney Int 2008, 74:571-576.
    • (2008) Kidney Int , vol.74 , pp. 571-576
    • Fried, L.F.1
  • 43
    • 34547743999 scopus 로고    scopus 로고
    • Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice
    • Fujii M., Inoguchi T., Maeda Y., et al. Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. Kidney Int 2007, 72:473-480.
    • (2007) Kidney Int , vol.72 , pp. 473-480
    • Fujii, M.1    Inoguchi, T.2    Maeda, Y.3
  • 44
    • 33645455275 scopus 로고    scopus 로고
    • Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling
    • Shibata S., Nagase M., Fujita T. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol 2006, 17:754-764.
    • (2006) J Am Soc Nephrol , vol.17 , pp. 754-764
    • Shibata, S.1    Nagase, M.2    Fujita, T.3
  • 45
    • 33746673912 scopus 로고    scopus 로고
    • Meta-analysis: the effect of statins on albuminuria
    • Douglas K., O'Malley P.G., Jackson J.L. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006, 145:117-124.
    • (2006) Ann Intern Med , vol.145 , pp. 117-124
    • Douglas, K.1    O'Malley, P.G.2    Jackson, J.L.3
  • 46
    • 78249284594 scopus 로고    scopus 로고
    • T-type Ca channel blockade as a determinant of kidney protection
    • Hayashi K., Homma K., Wakino S., et al. T-type Ca channel blockade as a determinant of kidney protection. Keio J Med 2010, 59:84-95.
    • (2010) Keio J Med , vol.59 , pp. 84-95
    • Hayashi, K.1    Homma, K.2    Wakino, S.3
  • 47
    • 73249126058 scopus 로고    scopus 로고
    • Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy
    • Sasaki H., Saiki A., Endo K., et al. Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. J Atheroscler Thromb 2009, 16:568-575.
    • (2009) J Atheroscler Thromb , vol.16 , pp. 568-575
    • Sasaki, H.1    Saiki, A.2    Endo, K.3
  • 48
    • 77956403931 scopus 로고    scopus 로고
    • Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats
    • Takai S., Jin D., Sakonjo H., Miyazaki M. Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats. Hypertens Res 2010, 33:953-959.
    • (2010) Hypertens Res , vol.33 , pp. 953-959
    • Takai, S.1    Jin, D.2    Sakonjo, H.3    Miyazaki, M.4
  • 49
    • 58949095363 scopus 로고    scopus 로고
    • Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy
    • Toto R.D., Tian M., Fakouhi K., Champion A., Bacher P. Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy. J Clin Hypertens (Greenwich) 2008, 10:761-769.
    • (2008) J Clin Hypertens (Greenwich) , vol.10 , pp. 761-769
    • Toto, R.D.1    Tian, M.2    Fakouhi, K.3    Champion, A.4    Bacher, P.5
  • 50
    • 34548028268 scopus 로고    scopus 로고
    • Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis
    • Ishimitsu T., Kameda T., Akashiba A., et al. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007, 30:621-626.
    • (2007) Hypertens Res , vol.30 , pp. 621-626
    • Ishimitsu, T.1    Kameda, T.2    Akashiba, A.3
  • 51
    • 36249006990 scopus 로고    scopus 로고
    • Rosiglitazone decreases albuminuria in type 2 diabetic patients
    • Miyazaki Y., Cersosimo E., Triplitt C., DeFronzo R.A. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 2007, 72:1367-1373.
    • (2007) Kidney Int , vol.72 , pp. 1367-1373
    • Miyazaki, Y.1    Cersosimo, E.2    Triplitt, C.3    DeFronzo, R.A.4
  • 52
    • 33646939809 scopus 로고    scopus 로고
    • Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone
    • Benigni A., Zoja C., Tomasoni S., et al. Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. J Am Soc Nephrol 2006, 17:1624-1632.
    • (2006) J Am Soc Nephrol , vol.17 , pp. 1624-1632
    • Benigni, A.1    Zoja, C.2    Tomasoni, S.3
  • 53
    • 0036116895 scopus 로고    scopus 로고
    • Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat
    • Yamashita H., Nagai Y., Takamura T., Nohara E., Kobayashi K. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. Metabolism 2002, 51:403-408.
    • (2002) Metabolism , vol.51 , pp. 403-408
    • Yamashita, H.1    Nagai, Y.2    Takamura, T.3    Nohara, E.4    Kobayashi, K.5
  • 54
    • 36649011357 scopus 로고    scopus 로고
    • Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model
    • Ohtomo S., Izuhara Y., Takizawa S., et al. Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model. Kidney Int 2007, 72:1512-1519.
    • (2007) Kidney Int , vol.72 , pp. 1512-1519
    • Ohtomo, S.1    Izuhara, Y.2    Takizawa, S.3
  • 56
    • 0036073755 scopus 로고    scopus 로고
    • 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system
    • Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110:229-238.
    • (2002) J Clin Invest , vol.110 , pp. 229-238
    • Li, Y.C.1    Kong, J.2    Wei, M.3    Chen, Z.F.4    Liu, S.Q.5    Cao, L.P.6
  • 57
    • 67651115709 scopus 로고    scopus 로고
    • Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats
    • Matsui I., Hamano T., Tomida K., et al. Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats. Nephrol Dial Transplant 2009, 24:2354-2361.
    • (2009) Nephrol Dial Transplant , vol.24 , pp. 2354-2361
    • Matsui, I.1    Hamano, T.2    Tomida, K.3
  • 58
    • 56549101354 scopus 로고    scopus 로고
    • Suppression of renin-angiotensin gene expression in the kidney by paricalcitol
    • Freundlich M., Quiroz Y., Zhang Z., et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008, 74:1394-1402.
    • (2008) Kidney Int , vol.74 , pp. 1394-1402
    • Freundlich, M.1    Quiroz, Y.2    Zhang, Z.3
  • 59
    • 78651384347 scopus 로고    scopus 로고
    • Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury
    • He W., Kang Y.S., Dai C., Liu Y. Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol 2011, 22:90-103.
    • (2011) J Am Soc Nephrol , vol.22 , pp. 90-103
    • He, W.1    Kang, Y.S.2    Dai, C.3    Liu, Y.4
  • 60
    • 59449105533 scopus 로고    scopus 로고
    • 1,25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway
    • Xiao H., Shi W., Liu S., et al. 1,25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway. Am J Nephrol 2009, 30:34-43.
    • (2009) Am J Nephrol , vol.30 , pp. 34-43
    • Xiao, H.1    Shi, W.2    Liu, S.3
  • 61
    • 78149359262 scopus 로고    scopus 로고
    • Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial
    • de Zeeuw D., Agarwal R., Amdahl M., et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010, 376:1543-1551.
    • (2010) Lancet , vol.376 , pp. 1543-1551
    • de Zeeuw, D.1    Agarwal, R.2    Amdahl, M.3
  • 62
  • 63
    • 0035954017 scopus 로고    scopus 로고
    • Use of pentoxifylline in membranous nephropathy
    • Ducloux D., Bresson-Vautrin C., Chalopin J. Use of pentoxifylline in membranous nephropathy. Lancet 2001, 357:1672-1673.
    • (2001) Lancet , vol.357 , pp. 1672-1673
    • Ducloux, D.1    Bresson-Vautrin, C.2    Chalopin, J.3
  • 64
    • 49949102418 scopus 로고    scopus 로고
    • Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial
    • Lin S.L., Chen Y.M., Chiang W.C., Wu K.D., Tsai T.J. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am J Kidney Dis 2008, 52:464-474.
    • (2008) Am J Kidney Dis , vol.52 , pp. 464-474
    • Lin, S.L.1    Chen, Y.M.2    Chiang, W.C.3    Wu, K.D.4    Tsai, T.J.5
  • 65
    • 13444271063 scopus 로고    scopus 로고
    • Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats
    • Leh S., Vaagnes O., Margolin S.B., Iversen B.M., Forslund T. Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats. Nephrol Dial Transplant 2005, 20:71-82.
    • (2005) Nephrol Dial Transplant , vol.20 , pp. 71-82
    • Leh, S.1    Vaagnes, O.2    Margolin, S.B.3    Iversen, B.M.4    Forslund, T.5
  • 66
    • 74149086684 scopus 로고    scopus 로고
    • Renoprotective properties of pirfenidone in subtotally nephrectomized rats
    • Takakuta K., Fujimori A., Chikanishi T., et al. Renoprotective properties of pirfenidone in subtotally nephrectomized rats. Eur J Pharmacol 2010, 629:118-124.
    • (2010) Eur J Pharmacol , vol.629 , pp. 118-124
    • Takakuta, K.1    Fujimori, A.2    Chikanishi, T.3
  • 67
    • 68149178848 scopus 로고    scopus 로고
    • Pirfenidone is renoprotective in diabetic kidney disease
    • RamachandraRao S.P., Zhu Y., Ravasi T., et al. Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 2009, 20:1765-1775.
    • (2009) J Am Soc Nephrol , vol.20 , pp. 1765-1775
    • RamachandraRao, S.P.1    Zhu, Y.2    Ravasi, T.3
  • 68
    • 34548834734 scopus 로고    scopus 로고
    • Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis
    • Cho M.E., Smith D.C., Branton M.H., Penzak S.R., Kopp J.B. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007, 2:906-913.
    • (2007) Clin J Am Soc Nephrol , vol.2 , pp. 906-913
    • Cho, M.E.1    Smith, D.C.2    Branton, M.H.3    Penzak, S.R.4    Kopp, J.B.5
  • 69
    • 2542447966 scopus 로고    scopus 로고
    • Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy
    • Mifsud S., Kelly D.J., Qi W., et al. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron Physiol 2003, 95:83-91.
    • (2003) Nephron Physiol , vol.95 , pp. 83-91
    • Mifsud, S.1    Kelly, D.J.2    Qi, W.3
  • 70
    • 16644370226 scopus 로고    scopus 로고
    • Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model
    • Kelly D.J., Zhang Y., Gow R., Gilbert R.E. Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model. J Am Soc Nephrol 2004, 15:2619-2629.
    • (2004) J Am Soc Nephrol , vol.15 , pp. 2619-2629
    • Kelly, D.J.1    Zhang, Y.2    Gow, R.3    Gilbert, R.E.4
  • 71
    • 33745239220 scopus 로고    scopus 로고
    • Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model
    • Kelly D.J., Zhang Y., Cox A.J., Gilbert R.E. Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model. Kidney Int 2006, 69:1954-1960.
    • (2006) Kidney Int , vol.69 , pp. 1954-1960
    • Kelly, D.J.1    Zhang, Y.2    Cox, A.J.3    Gilbert, R.E.4
  • 72
    • 46349104473 scopus 로고    scopus 로고
    • Tranilast ameliorates experimental mesangial proliferative glomerulonephritis
    • Tokuyama H., Kelly D.J., Cox A., et al. Tranilast ameliorates experimental mesangial proliferative glomerulonephritis. Nephron Exp Nephrol 2008, 109:e1-e7.
    • (2008) Nephron Exp Nephrol , vol.109
    • Tokuyama, H.1    Kelly, D.J.2    Cox, A.3
  • 73
    • 0037015262 scopus 로고    scopus 로고
    • Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial
    • Holmes D.R., Savage M., LaBlanche J.M., et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2002, 106:1243-1250.
    • (2002) Circulation , vol.106 , pp. 1243-1250
    • Holmes, D.R.1    Savage, M.2    LaBlanche, J.M.3
  • 74
    • 0036362822 scopus 로고    scopus 로고
    • Tranilast slows the progression of advanced diabetic nephropathy
    • Soma J., Sugawara T., Huang Y.D., Nakajima J., Kawamura M. Tranilast slows the progression of advanced diabetic nephropathy. Nephron 2002, 92:693-698.
    • (2002) Nephron , vol.92 , pp. 693-698
    • Soma, J.1    Sugawara, T.2    Huang, Y.D.3    Nakajima, J.4    Kawamura, M.5
  • 75
    • 33749618332 scopus 로고    scopus 로고
    • Effect of tranilast in early-stage diabetic nephropathy
    • Soma J., Sato K., Saito H., Tsuchiya Y. Effect of tranilast in early-stage diabetic nephropathy. Nephrol Dial Transplant 2006, 21:2795-2799.
    • (2006) Nephrol Dial Transplant , vol.21 , pp. 2795-2799
    • Soma, J.1    Sato, K.2    Saito, H.3    Tsuchiya, Y.4
  • 76
    • 77955865476 scopus 로고    scopus 로고
    • Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro
    • Chen Z.H., Qin W.S., Zeng C.H., et al. Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Kidney Int 2010, 77:974-988.
    • (2010) Kidney Int , vol.77 , pp. 974-988
    • Chen, Z.H.1    Qin, W.S.2    Zeng, C.H.3
  • 77
    • 49749123825 scopus 로고    scopus 로고
    • Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro
    • Zheng C.X., Chen Z.H., Zeng C.H., Qin W.S., Li L.S., Liu Z.H. Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro. Kidney Int 2008, 74:596-612.
    • (2008) Kidney Int , vol.74 , pp. 596-612
    • Zheng, C.X.1    Chen, Z.H.2    Zeng, C.H.3    Qin, W.S.4    Li, L.S.5    Liu, Z.H.6
  • 78
    • 67049110419 scopus 로고    scopus 로고
    • Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours
    • Kitzen J.J., de Jonge M.J., Lamers C.H., et al. Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. Eur J Cancer 2009, 45:1764-1772.
    • (2009) Eur J Cancer , vol.45 , pp. 1764-1772
    • Kitzen, J.J.1    de Jonge, M.J.2    Lamers, C.H.3
  • 79
    • 0026758529 scopus 로고
    • Effect of dipyridamole with or without aspirin on urine protein excretion in patients with membranous glomerulonephritis
    • De La Cruz J.P., Camara S., Frutos M.A., Sanchez De La Cuesta F. Effect of dipyridamole with or without aspirin on urine protein excretion in patients with membranous glomerulonephritis. Eur J Clin Pharmacol 1992, 43:307-309.
    • (1992) Eur J Clin Pharmacol , vol.43 , pp. 307-309
    • De La Cruz, J.P.1    Camara, S.2    Frutos, M.A.3    Sanchez De La Cuesta, F.4
  • 80
    • 0043032930 scopus 로고    scopus 로고
    • Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria
    • Kano K., Nishikura K., Yamada Y., Arisaka O. Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria. Clin Nephrol 2003, 60:85-89.
    • (2003) Clin Nephrol , vol.60 , pp. 85-89
    • Kano, K.1    Nishikura, K.2    Yamada, Y.3    Arisaka, O.4
  • 81
    • 33845743504 scopus 로고    scopus 로고
    • Meta-analysis of antiplatelet therapy for IgA nephropathy
    • Taji Y., Kuwahara T., Shikata S., Morimoto T. Meta-analysis of antiplatelet therapy for IgA nephropathy. Clin Exp Nephrol 2006, 10:268-273.
    • (2006) Clin Exp Nephrol , vol.10 , pp. 268-273
    • Taji, Y.1    Kuwahara, T.2    Shikata, S.3    Morimoto, T.4
  • 82
    • 33751404292 scopus 로고    scopus 로고
    • Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial
    • Yoshikawa N., Honda M., Iijima K., et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol 2006, 1:511-517.
    • (2006) Clin J Am Soc Nephrol , vol.1 , pp. 511-517
    • Yoshikawa, N.1    Honda, M.2    Iijima, K.3
  • 83
    • 0033855993 scopus 로고    scopus 로고
    • Effect of the antiplatelet drug dilazep dihydrochloride on urinary podocytes in patients in the early stage of diabetic nephropathy
    • Nakamura T., Ushiyama C., Shimada N., et al. Effect of the antiplatelet drug dilazep dihydrochloride on urinary podocytes in patients in the early stage of diabetic nephropathy. Diabetes Care 2000, 23:1168-1171.
    • (2000) Diabetes Care , vol.23 , pp. 1168-1171
    • Nakamura, T.1    Ushiyama, C.2    Shimada, N.3
  • 84
    • 78649926915 scopus 로고    scopus 로고
    • Darbepoetin-alpha treatment enhances glomerular regenerative process in the Thy-1 glomerulonephritis model
    • Canadillas S., Ortega R., Estepa J.C., et al. Darbepoetin-alpha treatment enhances glomerular regenerative process in the Thy-1 glomerulonephritis model. Am J Physiol Renal Physiol 2010, 299:F1278-F1287.
    • (2010) Am J Physiol Renal Physiol , vol.299
    • Canadillas, S.1    Ortega, R.2    Estepa, J.C.3
  • 85
    • 34547815735 scopus 로고    scopus 로고
    • Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression
    • Eto N., Wada T., Inagi R., et al. Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int 2007, 72:455-463.
    • (2007) Kidney Int , vol.72 , pp. 455-463
    • Eto, N.1    Wada, T.2    Inagi, R.3
  • 87
    • 3042677677 scopus 로고    scopus 로고
    • Rhu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline
    • Tapolyai M., Kadomatsu S., Perera-Chong M. rhu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline. BMC Nephrol 2003, 4:3.
    • (2003) BMC Nephrol , vol.4 , pp. 3
    • Tapolyai, M.1    Kadomatsu, S.2    Perera-Chong, M.3
  • 88
    • 22744457129 scopus 로고    scopus 로고
    • Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease
    • Dean B.B., Dylan M., Gano A., Knight K., Ofman J.J., Levine B.S. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 2005, 21:981-987.
    • (2005) Curr Med Res Opin , vol.21 , pp. 981-987
    • Dean, B.B.1    Dylan, M.2    Gano, A.3    Knight, K.4    Ofman, J.J.5    Levine, B.S.6
  • 89
    • 33751002326 scopus 로고    scopus 로고
    • Normalization of hemoglobin level in patients with chronic kidney disease and anemia
    • Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355:2071-2084.
    • (2006) N Engl J Med , vol.355 , pp. 2071-2084
    • Drueke, T.B.1    Locatelli, F.2    Clyne, N.3
  • 90
    • 33750983605 scopus 로고    scopus 로고
    • Correction of anemia with epoetin alfa in chronic kidney disease
    • Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098.
    • (2006) N Engl J Med , vol.355 , pp. 2085-2098
    • Singh, A.K.1    Szczech, L.2    Tang, K.L.3
  • 92
    • 53549090148 scopus 로고    scopus 로고
    • Agents in development for the treatment of diabetic nephropathy
    • Goh S.Y., Jasik M., Cooper M.E. Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs 2008, 13:447-463.
    • (2008) Expert Opin Emerg Drugs , vol.13 , pp. 447-463
    • Goh, S.Y.1    Jasik, M.2    Cooper, M.E.3
  • 94
    • 70349277003 scopus 로고    scopus 로고
    • Effects of angiotensin II receptor blockers on diabetic nephropathy
    • Kalaitzidis R., Bakris G.L. Effects of angiotensin II receptor blockers on diabetic nephropathy. J Hypertens Suppl 2009, 27:S15-S21.
    • (2009) J Hypertens Suppl , vol.27
    • Kalaitzidis, R.1    Bakris, G.L.2
  • 95
    • 0032712434 scopus 로고    scopus 로고
    • Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes
    • Cooper M.E., Vranes D., Youssef S., et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999, 48:2229-2239.
    • (1999) Diabetes , vol.48 , pp. 2229-2239
    • Cooper, M.E.1    Vranes, D.2    Youssef, S.3
  • 96
    • 0035034655 scopus 로고    scopus 로고
    • Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes
    • de Vriese A.S., Tilton R.G., Elger M., Stephan C.C., Kriz W., Lameire N.H. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001, 12:993-1000.
    • (2001) J Am Soc Nephrol , vol.12 , pp. 993-1000
    • de Vriese, A.S.1    Tilton, R.G.2    Elger, M.3    Stephan, C.C.4    Kriz, W.5    Lameire, N.H.6
  • 97
    • 85047697288 scopus 로고    scopus 로고
    • 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice
    • Ichinose K., Maeshima Y., Yamamoto Y., et al. 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes 2006, 55:1232-1242.
    • (2006) Diabetes , vol.55 , pp. 1232-1242
    • Ichinose, K.1    Maeshima, Y.2    Yamamoto, Y.3
  • 98
    • 33750713086 scopus 로고    scopus 로고
    • Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice
    • Sung S.H., Ziyadeh F.N., Wang A., Pyagay P.E., Kanwar Y.S., Chen S. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006, 17:3093-3104.
    • (2006) J Am Soc Nephrol , vol.17 , pp. 3093-3104
    • Sung, S.H.1    Ziyadeh, F.N.2    Wang, A.3    Pyagay, P.E.4    Kanwar, Y.S.5    Chen, S.6
  • 99
    • 48649099815 scopus 로고    scopus 로고
    • The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease
    • Eardley K.S., Kubal C., Zehnder D., et al. The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int 2008, 74:495-504.
    • (2008) Kidney Int , vol.74 , pp. 495-504
    • Eardley, K.S.1    Kubal, C.2    Zehnder, D.3
  • 100
    • 60549110804 scopus 로고    scopus 로고
    • Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response
    • Yan S.F., Ramasamy R., Schmidt A.M. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med 2009, 87:235-247.
    • (2009) J Mol Med , vol.87 , pp. 235-247
    • Yan, S.F.1    Ramasamy, R.2    Schmidt, A.M.3
  • 101
    • 0033848466 scopus 로고    scopus 로고
    • Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease
    • Tanji N., Markowitz G.S., Fu C., et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000, 11:1656-1666.
    • (2000) J Am Soc Nephrol , vol.11 , pp. 1656-1666
    • Tanji, N.1    Markowitz, G.S.2    Fu, C.3
  • 102
    • 44049098885 scopus 로고    scopus 로고
    • RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis
    • Guo J., Ananthakrishnan R., Qu W., et al. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J Am Soc Nephrol 2008, 19:961-972.
    • (2008) J Am Soc Nephrol , vol.19 , pp. 961-972
    • Guo, J.1    Ananthakrishnan, R.2    Qu, W.3
  • 103
    • 0037377697 scopus 로고    scopus 로고
    • RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy
    • Wendt T.M., Tanji N., Guo J., et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003, 162:1123-1137.
    • (2003) Am J Pathol , vol.162 , pp. 1123-1137
    • Wendt, T.M.1    Tanji, N.2    Guo, J.3
  • 104
    • 0942290502 scopus 로고    scopus 로고
    • Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat
    • Davis B.J., Forbes J.M., Thomas M.C., et al. Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia 2004, 47:89-97.
    • (2004) Diabetologia , vol.47 , pp. 89-97
    • Davis, B.J.1    Forbes, J.M.2    Thomas, M.C.3
  • 105
    • 77649119983 scopus 로고    scopus 로고
    • Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy
    • Tan A.L., Sourris K.C., Harcourt B.E., et al. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2010, 298:F763-F770.
    • (2010) Am J Physiol Renal Physiol , vol.298
    • Tan, A.L.1    Sourris, K.C.2    Harcourt, B.E.3
  • 106
    • 77951622247 scopus 로고    scopus 로고
    • Potential new therapeutic agents for diabetic kidney disease
    • Turgut F., Bolton W.K. Potential new therapeutic agents for diabetic kidney disease. Am J Kidney Dis 2010, 55:928-940.
    • (2010) Am J Kidney Dis , vol.55 , pp. 928-940
    • Turgut, F.1    Bolton, W.K.2
  • 107
    • 72449124626 scopus 로고    scopus 로고
    • The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice
    • Watson A.M., Li J., Schumacher C., et al. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 2010, 53:192-203.
    • (2010) Diabetologia , vol.53 , pp. 192-203
    • Watson, A.M.1    Li, J.2    Schumacher, C.3
  • 108
    • 62149126622 scopus 로고    scopus 로고
    • Avosentan reduces albumin excretion in diabetics with macroalbuminuria
    • Wenzel R.R., Littke T., Kuranoff S., et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009, 20:655-664.
    • (2009) J Am Soc Nephrol , vol.20 , pp. 655-664
    • Wenzel, R.R.1    Littke, T.2    Kuranoff, S.3
  • 109
    • 77949877308 scopus 로고    scopus 로고
    • Avosentan for overt diabetic nephropathy
    • Mann J.F., Green D., Jamerson K., et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010, 21:527-535.
    • (2010) J Am Soc Nephrol , vol.21 , pp. 527-535
    • Mann, J.F.1    Green, D.2    Jamerson, K.3
  • 110
  • 111
    • 77951199503 scopus 로고    scopus 로고
    • The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy
    • Jiang T., Huang Z., Lin Y., Zhang Z., Fang D., Zhang D.D. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 2010, 59:850-860.
    • (2010) Diabetes , vol.59 , pp. 850-860
    • Jiang, T.1    Huang, Z.2    Lin, Y.3    Zhang, Z.4    Fang, D.5    Zhang, D.D.6
  • 112
    • 79953242026 scopus 로고    scopus 로고
    • New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress
    • Sporn M.B., Liby K.T., Yore M.M., Fu L., Lopchuk J.M., Gribble G.W. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod 2011, 74:537-545.
    • (2011) J Nat Prod , vol.74 , pp. 537-545
    • Sporn, M.B.1    Liby, K.T.2    Yore, M.M.3    Fu, L.4    Lopchuk, J.M.5    Gribble, G.W.6
  • 113
    • 13344293711 scopus 로고    scopus 로고
    • Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor
    • Ishii H., Jirousek M.R., Koya D., et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996, 272:728-731.
    • (1996) Science , vol.272 , pp. 728-731
    • Ishii, H.1    Jirousek, M.R.2    Koya, D.3
  • 114
    • 0034053336 scopus 로고    scopus 로고
    • Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes
    • Koya D., Haneda M., Nakagawa H., et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000, 14:439-447.
    • (2000) FASEB J , vol.14 , pp. 439-447
    • Koya, D.1    Haneda, M.2    Nakagawa, H.3
  • 117
    • 20544477176 scopus 로고    scopus 로고
    • Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice
    • Lassila M., Jandeleit-Dahm K., Seah K.K., et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 2005, 16:363-373.
    • (2005) J Am Soc Nephrol , vol.16 , pp. 363-373
    • Lassila, M.1    Jandeleit-Dahm, K.2    Seah, K.K.3
  • 118
    • 77953013434 scopus 로고    scopus 로고
    • Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy
    • Rossini M., Naito T., Yang H., et al. Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy. Nephrol Dial Transplant 2010, 25:1803-1810.
    • (2010) Nephrol Dial Transplant , vol.25 , pp. 1803-1810
    • Rossini, M.1    Naito, T.2    Yang, H.3
  • 120
    • 77955440687 scopus 로고    scopus 로고
    • Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy
    • Blouza S., Dakhli S., Abid H., et al. Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. J Nephrol 2010, 23:415-424.
    • (2010) J Nephrol , vol.23 , pp. 415-424
    • Blouza, S.1    Dakhli, S.2    Abid, H.3
  • 121
    • 78649318718 scopus 로고    scopus 로고
    • Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus
    • Broekhuizen L.N., Lemkes B.A., Mooij H.L., et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010, 53:2646-2655.
    • (2010) Diabetologia , vol.53 , pp. 2646-2655
    • Broekhuizen, L.N.1    Lemkes, B.A.2    Mooij, H.L.3
  • 122
    • 51749093569 scopus 로고    scopus 로고
    • Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials
    • Pan Y., Guo L.L., Jin H.M. Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2008, 88:660-666.
    • (2008) Am J Clin Nutr , vol.88 , pp. 660-666
    • Pan, Y.1    Guo, L.L.2    Jin, H.M.3
  • 123
    • 0035022816 scopus 로고    scopus 로고
    • Dietary phytoestrogens: a possible role in renal disease protection
    • Velasquez M.T., Bhathena S.J. Dietary phytoestrogens: a possible role in renal disease protection. Am J Kidney Dis 2001, 37:1056-1068.
    • (2001) Am J Kidney Dis , vol.37 , pp. 1056-1068
    • Velasquez, M.T.1    Bhathena, S.J.2
  • 124
    • 60449105133 scopus 로고    scopus 로고
    • The ethyl acetate extract of alfalfa sprout ameliorates disease severity of autoimmune-prone MRL-lpr/lpr mice
    • Hong Y.H., Huang C.J., Wang S.C., Lin B.F. The ethyl acetate extract of alfalfa sprout ameliorates disease severity of autoimmune-prone MRL-lpr/lpr mice. Lupus 2009, 18:206-215.
    • (2009) Lupus , vol.18 , pp. 206-215
    • Hong, Y.H.1    Huang, C.J.2    Wang, S.C.3    Lin, B.F.4
  • 125
    • 65949101874 scopus 로고    scopus 로고
    • Moderate exercise attenuates caspase-3 activity, oxidative stress, and inhibits progression of diabetic renal disease in db/db mice
    • Ghosh S., Khazaei M., Moien-Afshari F., et al. Moderate exercise attenuates caspase-3 activity, oxidative stress, and inhibits progression of diabetic renal disease in db/db mice. Am J Physiol Renal Physiol 2009, 296:F700-F708.
    • (2009) Am J Physiol Renal Physiol , vol.296
    • Ghosh, S.1    Khazaei, M.2    Moien-Afshari, F.3
  • 126
    • 78049292766 scopus 로고    scopus 로고
    • Weight loss: a neglected intervention in the management of chronic kidney disease
    • Ibrahim H.N., Weber M.L. Weight loss: a neglected intervention in the management of chronic kidney disease. Curr Opin Nephrol Hypertens 2010, 19:534-538.
    • (2010) Curr Opin Nephrol Hypertens , vol.19 , pp. 534-538
    • Ibrahim, H.N.1    Weber, M.L.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.